Form 4: Director Athena Countouriotis Acquires Stock Options

Director Athena Countouriotis acquired 10,539 stock options in Passage BIO, Inc. on May 19, 2026, with an exercise price of $5.08.

Summary

• Athena Countouriotis, a Director at Passage BIO, Inc., acquired 10,539 stock options on May 19, 2026.
• The stock options have an exercise price of $5.08 per share.
• These options are exercisable and will vest in full on the earlier of the one-year anniversary of the grant date or the date of the issuer's 2027 Annual Meeting of stockholders, provided continuous service is maintained.
• The options are set to expire on May 19, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it indicates a director's commitment and potential belief in the company's future, but it does not represent new financial performance data.

Positives

• Director acquisition of stock options signals confidence in the company's future prospects.
• The grant of options aligns the director's interests with those of shareholders.
• The vesting schedule encourages long-term commitment and service to the company.

Risks

• The value of the stock options is subject to the future performance of Passage BIO, Inc.'s stock price.
• The vesting of options is contingent upon the reporting person's continuous service to the issuer.

Future Outlook

The stock options are set to vest on the earlier of the one-year anniversary of the grant date or the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service. The options expire on May 19, 2036.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology sector, often used as a long-term incentive to align executive interests with shareholder value and to retain key talent.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as a sign of confidence, potentially aligning director and shareholder interests.
• Employees: The vesting schedule for the director's options may indirectly influence employee incentive structures.
• Management: Reinforces the use of equity-based compensation as a tool for director retention and motivation.

Next Steps

• Continuous service by Athena Countouriotis to Passage BIO, Inc. until the vesting date.
• Potential exercise of stock options upon vesting and expiration.

Key Dates

Keywords

Form 4, Stock Options, Insider Trading, Passage BIO, Athena Countouriotis, SEC Filing, Beneficial Ownership, Director